The estimated Net Worth of Donald Notman is at least $2.52 million dollars as of 3 February 2024. Mr. Notman owns over 6,212 units of Ocular Therapeutix Inc stock worth over $1,648,805 and over the last 7 years he sold OCUL stock worth over $89,492. In addition, he makes $777,410 as Chief Financial Officer at Ocular Therapeutix Inc.
Donald has made over 6 trades of the Ocular Therapeutix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,212 units of OCUL stock worth $30,190 on 3 February 2024.
The largest trade he's ever made was buying 12,500 units of Ocular Therapeutix Inc stock on 14 August 2018 worth over $78,625. On average, Donald trades about 2,780 units every 161 days since 2017. As of 3 February 2024 he still owns at least 195,356 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. Notman stock trades at the bottom of the page.
Donald D. Notman Jr. serves as Chief Financial Officer of the Company. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College.
As the Chief Financial Officer of Ocular Therapeutix Inc, the total compensation of Donald Notman at Ocular Therapeutix Inc is $777,410. There are 4 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
Donald Notman is 60, he's been the Chief Financial Officer of Ocular Therapeutix Inc since 2019. There are 5 older and 10 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Donald's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer et Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: